SeaStar Medical Reports Fourfold Increase in QUELIMMUNE Sales, Targets Adult Market
SeaStar Medical reports significant growth in QUELIMMUNE sales and sets sights on the adult AKI market. The company's innovative therapy shows promise for improving patient outcomes and could have a substantial impact on the healthcare industry.
This news matters as SeaStar's innovative therapy is showing promising results in pediatric AKI patients, with plans to enter the larger adult AKI market. The company's growth and potential approval for adult AKI indication could significantly impact the healthcare industry and patient outcomes.
